| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
55,671,000 |
| Market
Cap: |
78.22(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.2 - $11.21 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Marinus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for patients suffering from rare genetic epilepsies and other seizure disorders. The U.S Food and Drug Administration approved the use of ZTALMY® (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients two years of age and older. Ganaxolone is being developed in formulations for various routes of administration: intravenous and oral. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A receptors, a target known for its anti-seizure, antidepressant and anxiolytic potential.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
21,803 |
21,803 |
38,528 |
41,369 |
| Total Sell Value |
$215,409 |
$215,409 |
$374,962 |
$393,504 |
| Total People Sold |
5 |
5 |
5 |
8 |
| Total Sell Transactions |
5 |
5 |
15 |
18 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cashman Christopher Michael |
CEO |
• • – |
2019-01-28 |
4 |
S |
$3.13 |
$25,484 |
D/D |
(8,142) |
239,761 |
|
- |
|
| Smith Edward F |
CFO |
• – – |
2018-01-29 |
4 |
S |
$7.91 |
$23,730 |
D/D |
(3,000) |
49,800 |
|
- |
|
| Vitullo Nicole |
Director |
– • – |
2018-01-22 |
4 |
A |
$0.00 |
$0 |
I/I |
2,250 |
46,450 |
|
- |
|
| Vitullo Nicole |
Director |
– • – |
2018-01-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,250) |
3,900 |
|
- |
|
| Cashman Christopher Michael |
CEO |
• • – |
2018-01-18 |
4 |
S |
$6.28 |
$60,074 |
D/D |
(9,566) |
247,903 |
|
- |
|
| Koppel Adam |
10% Owner |
– – • |
2017-12-19 |
4 |
S |
$7.11 |
$1,114,670 |
I/I |
(150,000) |
3,977,453 |
|
- |
|
| Koppel Adam |
10% Owner |
– – • |
2017-12-18 |
4 |
S |
$7.50 |
$2,251,440 |
I/I |
(300,000) |
4,127,453 |
|
- |
|
| Koppel Adam |
10% Owner |
– – • |
2017-12-15 |
4 |
S |
$8.02 |
$6,658,691 |
I/I |
(822,547) |
4,427,453 |
|
- |
|
| Vitullo Nicole |
Director |
– • – |
2017-09-11 |
4 |
A |
$0.00 |
$0 |
I/I |
1,650 |
44,200 |
|
- |
|
| Vitullo Nicole |
Director |
– • – |
2017-09-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,650) |
6,150 |
|
- |
|
| Dougherty Michael R |
Director |
– • – |
2017-02-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,000 |
|
- |
|
| Carrazana Enrique J. |
Director |
– • – |
2017-01-17 |
4/A |
A |
$0.00 |
$0 |
D/D |
28,500 |
31,800 |
|
- |
|
| Smith Edward F |
CFO |
• – – |
2017-01-17 |
4/A |
A |
$0.00 |
$0 |
D/D |
25,200 |
52,800 |
|
- |
|
| Mayleben Timothy M |
Director |
– • – |
2017-01-17 |
4/A |
A |
$0.00 |
$0 |
D/D |
4,500 |
50,350 |
|
- |
|
| Cashman Christopher Michael |
CEO |
• • – |
2017-01-17 |
4/A |
A |
$0.00 |
$0 |
D/D |
60,600 |
257,469 |
|
- |
|
| Vitullo Nicole |
Director |
– • • |
2017-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
7,800 |
|
- |
|
| Powell Michael |
10% Owner |
– – • |
2016-10-20 |
4 |
S |
$1.39 |
$1,042,699 |
I/I |
(750,683) |
15,470 |
|
- |
|
| Fischer Seth H.z. |
Director |
– • – |
2016-09-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,600 |
|
- |
|
| Canaan Partners Vii Llc |
10% Owner |
– – • |
2016-08-08 |
4 |
S |
$1.50 |
$29,925 |
I/I |
(19,950) |
1,850,783 |
|
- |
|
| Canaan Partners Vii Llc |
10% Owner |
– – • |
2016-08-05 |
4 |
S |
$1.50 |
$193,806 |
I/I |
(129,204) |
1,870,733 |
|
- |
|
| Canaan Partners Vii Llc |
10% Owner |
– – • |
2016-08-04 |
4 |
S |
$1.50 |
$4,994 |
I/I |
(3,329) |
1,999,937 |
|
- |
|
| Carrazana Enrique J. |
Director |
– • – |
2016-08-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
3,300 |
3,300 |
|
- |
|
| Mayleben Timothy M |
Director |
– • – |
2016-08-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
3,300 |
45,850 |
|
- |
|
| Smith Edward F |
CFO |
• – – |
2016-08-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
27,600 |
27,600 |
|
- |
|
| Cashman Christopher Michael |
CEO |
• • – |
2016-08-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
56,100 |
196,869 |
|
- |
|
129 Records found
|
|
Page 4 of 6 |
|
|
0.01 (1.06%) 
